SRR4195675
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.480
- INTERFERON_ALPHA_RESPONSE+0.480
- INTERFERON_GAMMA_RESPONSE+0.430
- MYC_TARGETS_V1+0.350
- ALLOGRAFT_REJECTION+0.330
- PROTEIN_SECRETION+0.290
- OXIDATIVE_PHOSPHORYLATION+0.210
- ANDROGEN_RESPONSE+0.200
- INFLAMMATORY_RESPONSE+0.200
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.380
- XENOBIOTIC_METABOLISM-0.380
- BILE_ACID_METABOLISM-0.370
- ANGIOGENESIS-0.360
- HYPOXIA-0.360
- MYOGENESIS-0.350
- COAGULATION-0.330
- HEDGEHOG_SIGNALING-0.320
- APICAL_JUNCTION-0.290
- NOTCH_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR4195655 | — | — | 0.863 |
| 2 | s0122212 | — | — | 0.847 |
| 3 | 90c9f8cd-4c8c-4f07-af2f-e17db69bd561 | — | — | 0.816 |
| 4 | SRR12475138 | — | — | 0.812 |
| 5 | SRR8518162 | — | E | 0.811 |
| 6 | MNG724 | — | — | 0.808 |
| 7 | b25e7003-40df-4806-baee-eb8ad1c69643 | — | — | 0.808 |
| 8 | SRR2016949 | — | — | 0.803 |
| 9 | 1b0a23c2-785d-4a14-b673-86c97ceff401 | — | — | 0.782 |
| 10 | MBCProject_1542_T2_RNA | — | D | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.330 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.210 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.030 | Idelalisib | — uncovered |